Radu Dobrin is Chief Scientific Officer at Evozyne, where he leads the company’s scientific strategy and the integration of AI, protein design, and drug discovery to engineer novel therapeutics.

Dr. Dobrin has spent his career at the intersection of computational science, experimental biology, and medicine, building technologies and scientific organizations that turn large-scale biological data into therapeutic insight. Prior to Evozyne, he served as Chief Technology Officer at Deep Genomics. He has held senior leadership roles at Pathos AI, Tempus AI, Bristol Myers Squibb, and Johnson & Johnson, spanning AI-enabled drug discovery, translational science, immunology, and oncology.

He holds a PhD in Physics from Michigan State University. His work is driven by the belief that AI becomes most impactful in drug discovery when prediction and experiment operate as a continuous learning system.